首页> 美国卫生研究院文献>BioResearch Open Access >Microcarrier Culture for Efficient Expansion and Osteogenic Differentiation of Human Fetal Mesenchymal Stem Cells
【2h】

Microcarrier Culture for Efficient Expansion and Osteogenic Differentiation of Human Fetal Mesenchymal Stem Cells

机译:微载体培养的人胎儿间充质干细胞的有效扩增和成骨分化。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Stirred microcarrier (MC) culture has been suggested as the method of choice for supplying large volumes of mesenchymal stem cells (MSCs) for bone tissue engineering. In this study, we show that in addition to the improvement in cell expansion capacity, MSCs propagated and harvested from MC culture also demonstrate higher osteogenic potency when differentiated in vivo or in vitro in three-dimensional (3D) scaffold cultures as compared with traditional monolayer (MNL) cultures. Cytodex 3 microcarrier-expanded human fetal MSC (hfMSC) cultures (MC-hfMSCs) achieved 12- to 16-fold expansion efficiency (6×105–8×105 cells/mL) compared to 4- to 6-fold (1.2×105–1.8×105 cells/mL) achieved by traditional MNL-expanded hfMSC culture (MNL-hfMSCs; p<0.05). Both MC-hfMSCs and MNL-hfMSCs maintained similar colony-forming capacity, doubling times, and immunophenotype postexpansion. However, when differentiated under in vitro two-dimensional (2D) osteogenic conditions, MC-hfMSCs exhibited a 45-fold reduction in alkaline phosphatase level and a 37.5% decrease in calcium deposition compared with MNL-hfMSCs (p<0.05). Surprisingly, when MC-hfMSCs and MNL-hfMSCs were seeded on 3D macroporous scaffold culture or subcutaneously implanted into nonobese diabetic/severe combined immunodeficient mice, MC-hfMSCs deposited 63.5% (p<0.05) more calcium and formed 47.2% (p<0.05) more bone volume, respectively. These results suggest that the mode of hfMSC growth in the expansion phase affects the osteogenic potential of hfMSCs differently in various differentiation platforms. In conclusion, MC cultures are advantageous over MNL cultures in bone tissue engineering because MC-hfMSCs have improved cell expansion capacity and exhibit higher osteogenic potential than MNL-hfMSCs when seeded in vitro into 3D scaffolds or implanted in vivo.
机译:已建议将搅拌微载体(MC)培养作为为骨组织工程提供大量间充质干细胞(MSC)的选择方法。在这项研究中,我们表明,除了改善细胞扩增能力外,从MC培养物中繁殖和收获的MSC与传统单层相比,在体内或体外在三维(3D)支架培养物中分化时,还显示出更高的成骨能力(MNL)文化。 Cytodex 3微载体扩增的人类胎儿MSC(hfMSC)培养物(MC-hfMSCs)达到12至16倍的扩增效率(6×10 5 –8×10 5 细胞/ mL)与传统MNL扩展的hfMSC培养(MNL)获得的4至6倍(1.2×10 5 –1.8×10 5 细胞/ mL)相比-hfMSC; p <0.05)。 MC-hfMSC和MNL-hfMSC都保持相似的菌落形成能力,倍增时间和扩增后的免疫表型。但是,当在体外二维(2D)成骨条件下进行分化时,与MNL-hfMSC相比,MC-hfMSC的碱性磷酸酶水平降低了45倍,钙沉积降低了37.5%(p <0.05)。令人惊讶的是,当将MC-hfMSCs和MNL-hfMSCs接种在3D大孔支架培养物中或皮下植入非肥胖型糖尿病/重度联合免疫缺陷小鼠中时,MC-hfMSCs沉积了63.5%(p <0.05)的钙,形成了47.2%(p <0.05) )分别有更多的骨量。这些结果表明,hfMSC在扩展阶段的生长方式在各种分化平台上对hfMSC的成骨潜能有不同的影响。总之,在体外组织植入3D支架或体内植入时,MC-hfMSC具有比MNL-hfMSC更高的细胞扩增能力,并具有更高的成骨潜能,因此在骨组织工程中MC培养优于MNL培养。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号